Sacubitril/Valsartan-Related Hypotension in Patients With Heart Failure and Preserved or Mildly Reduced Ejection Fraction
Abstract
No abstract availableKeywords
Funding Information
- Novartis Pharmaceuticals Corp
This publication has 15 references indexed in Scilit:
- Angiotensin-Neprilysin Inhibition in Patients With Mildly Reduced or Preserved Ejection Fraction and Worsening Heart FailureJACC, 2023
- 2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection FractionJACC, 2023
- A Reclassification of Heart Failure Based on Recognition of Heart Failure with Normal to Supernormal Ejection Fraction, a Clinically Common form of Cardiac Contracture, with Distinctive Pathophysiological and Therapeutic FeaturesEuropean Journal of Heart Failure, 2023
- Ventricular Stiffening and Chamber Contracture in Heart Failure with Higher Ejection FractionEuropean Journal of Heart Failure, 2023
- 2022 AHA/ACC/HFSA Guideline for the Management of Heart FailureJACC, 2022
- Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart FailureNew England Journal of Medicine, 2019
- Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection FractionJACC: Heart Failure, 2017
- Angiotensin–Neprilysin Inhibition versus Enalapril in Heart FailureNew England Journal of Medicine, 2014
- Effects of Vasodilation in Heart Failure With Preserved or Reduced Ejection FractionJACC, 2012
- Association of systolic blood pressure with mortality in patients with heart failure with reduced ejection fraction: A complex relationshipAmerican Heart Journal, 2011